Stem Cell Therapy for Knees: What the Studies Show — and Where They Disagree
Medically reviewed by Dr. Charles Pereyra, MD — Medical Director, Springs Rejuvenation. Last reviewed November 11, 2026.
Written by the Springs Rejuvenation regenerative medicine team from direct clinical experience administering stem cell and exosome protocols at our Aventura, Miami center.
The published research on stem cell therapy for knees shows a pattern of modest improvements in pain and function in some small studies, mixed results in others, and wide variation in individual response—not the uniform success stories sometimes seen in marketing. Most trials remain early-stage, measures of effectiveness differ, and the therapy is investigational and not FDA approved.
Understanding what the evidence actually supports, where it remains incomplete, and how physicians screen candidates can help you have a more informed conversation about whether regenerative approaches—or conventional options like physical therapy, corticosteroid injections, or surgery—make sense for your situation.
What Does the Research Actually Say About Stem Cell Therapy for Knees?
Published trials of mesenchymal stem cells (MSCs) for knee osteoarthritis typically measure pain reduction, improvement in physical function, and sometimes cartilage thickness on imaging. Most studies report that some participants experience moderate pain relief and better mobility six to twelve months after injection, while others see little change.
The results are rarely dramatic and almost never universal. Outcome measures vary from study to study—some use validated pain scales, others track range of motion or MRI findings—making direct comparisons difficult. Many trials are small, unblinded, or lack long-term follow-up beyond one to two years.
One reason for inconsistent results may lie in how cells navigate to damaged tissue. Yamada and colleagues (2018) identified a signaling pathway—the S1P–S1PR2 axis—that appears to guide intravenously delivered cells toward areas of injury, but the efficiency of that homing mechanism in human knees remains an active area of investigation.
Safety data from larger intravenous MSC trials, including an early safety study by Hare and colleagues (2009), have generally shown that systemically delivered stem cells are well tolerated in the short term, though long-term safety data in musculoskeletal applications remain limited.
A later study by Bartolucci and colleagues (2017) examined intravenous delivery of umbilical-cord MSCs and found modest functional improvements in some participants, reinforcing the idea that cell-based therapies can be administered safely but with variable clinical benefit. That variability is a consistent theme across the literature.
How Do Stem Cell Therapy for Knees Compare to Other Options?
Knee pain from osteoarthritis, meniscal tears, or ligament injury can be addressed through a range of interventions. Each has its own evidence base, recovery timeline, and candidacy criteria. The table below outlines common approaches:
| Option | Mechanism | Typical Recovery | Evidence Level |
|---|---|---|---|
| Physical therapy | Strengthening and range-of-motion exercises | Weeks to months | Strong for mild to moderate arthritis |
| Corticosteroid injections | Anti-inflammatory; temporary symptom relief | Days to weeks; effect may last months | Well established; repeated use debated |
| Hyaluronic acid injections | Lubricates joint; may reduce friction | Weeks; effect variable | Mixed; some patients report benefit |
| Regenerative cell therapies | Investigational; aims to support tissue repair | Months to see effect; highly variable | Early-stage; not FDA approved |
| Partial or total knee replacement | Surgical replacement of damaged joint surfaces | Months; highly effective for severe arthritis | Strong; definitive for end-stage disease |
Physical therapy and corticosteroid injections are often first-line interventions for mild to moderate symptoms. Surgery becomes the discussion when conservative measures no longer provide adequate relief and imaging shows advanced joint damage. Regenerative approaches occupy a middle ground—investigational, variably effective, and best considered in consultation with a physician who can review your imaging, symptom severity, and overall health.
Dr. Charles Pereyra, MD, a board-certified emergency medicine physician who oversees candidacy screening, emphasizes that no single intervention is right for every patient. The decision involves weighing the stage of joint degeneration, prior responses to other therapies, and individual expectations.
Why Do Some Studies Show Promise While Others Don't?
The wide variation in published results reflects differences in cell type, dose, delivery method, patient selection, and outcome measures. Some trials use bone-marrow-derived MSCs, others use adipose or umbilical-cord sources. Doses range from millions to hundreds of millions of cells. Some studies deliver cells intra-articularly (directly into the joint), others intravenously.
Patient populations also differ. A trial enrolling people with mild arthritis and intact cartilage may report better outcomes than one that includes participants with bone-on-bone degeneration. Baseline severity matters, and not every study controls for it.
Outcome measures add another layer of complexity. Pain scales are subjective. MRI cartilage thickness can improve without corresponding symptom relief, or vice versa. Follow-up periods vary from six months to two years, and few studies track participants longer.
Noda and colleagues (2020) published a first-in-human Japanese safety study of a specific type of pluripotent stem cell known as Muse cells, demonstrating tolerability in a small cohort but leaving questions about efficacy open for further investigation. Niizuma and colleagues (2023) followed with a randomized, double-blind Japanese trial that showed modest results on some measures and no significant difference on others—a reminder that even well-designed studies can yield equivocal findings.
The honest takeaway is that stem cell therapy for knees is investigational. Individual responses vary widely, and no therapy has certain outcomes. Some people report meaningful improvement; others see little change. The science is early, the mechanisms are incompletely understood, and the literature includes both encouraging signals and null results.
Who Might Be a Candidate — and Who Should Consider Other Options First?
Physicians typically screen candidates based on imaging findings, symptom severity, prior interventions, and overall health. The goal is to identify people who might benefit from an investigational therapy while steering those with more advanced disease—or contraindications—toward established alternatives.
Often a good fit:
- Mild to moderate osteoarthritis with some remaining cartilage visible on MRI or X-ray
- Persistent pain despite physical therapy and conventional injections
- Motivated to defer surgery if a less-invasive option shows benefit
- Realistic expectations about investigational therapies
- No active infection, uncontrolled inflammatory conditions, or malignancy
Worth a conversation first:
- Severe bone-on-bone arthritis with minimal cartilage remaining
- Significant ligament instability or mechanical derangement requiring surgical repair
- Recent joint infection or inflammatory flare
- Unrealistic expectations about rapid or certain recovery
- Conditions that may complicate cell therapy (your physician will review)
Dr. Charles Pereyra notes that candidacy decisions are individualized. Imaging alone does not tell the full story—some people with moderate cartilage loss function well, while others with milder findings experience severe pain. A physician-led evaluation considers the whole picture.
What Does a Physician Look for Before Recommending Stem Cell Therapy?
A thorough candidacy evaluation typically includes a review of recent imaging—MRI is preferred for visualizing cartilage, menisci, and ligaments, though weight-bearing X-rays help assess joint-space narrowing and bone changes. Blood work may be ordered to rule out inflammatory or metabolic conditions that could affect healing or complicate therapy.
The physician will ask about your symptom timeline, prior therapies, activity level, and goals. Someone hoping to avoid knee replacement in the near term may have different expectations than someone seeking return to high-impact sports. Managing those expectations honestly is part of the screening process.
Physical examination assesses range of motion, stability, effusion, and pain patterns. Tenderness along the joint line, for example, may suggest meniscal pathology; instability may point to ligament injury. These findings help determine whether regenerative therapy is a reasonable option or whether surgery is more appropriate.
Lab work is not always necessary, but some physicians order inflammatory markers or metabolic panels to establish a baseline. The goal is to identify any systemic factors that could influence candidacy or outcomes.
Is Stem Cell Therapy for Knees FDA Approved?
No. Stem cell therapies for knee osteoarthritis and other musculoskeletal conditions are investigational and not FDA approved. The FDA regulates cell-based products as biologics, and most regenerative therapies currently offered fall under enforcement discretion or are considered minimally manipulated autologous cells (cells from your own body, processed and returned the same day).
That regulatory status does not mean the therapies are unsafe, but it does mean they have not undergone the large, multi-center, placebo-controlled trials required for formal approval. Patients considering stem cell therapy should understand that they are participating in an investigational approach with emerging evidence, not a validated standard of care.
Physician-supervised Muse cell therapy—a type of pluripotent stem cell identified by Kuroda, Dezawa, and colleagues (2010) and further characterized by Wakao, Dezawa, and colleagues (2011)—is available in the United States, meaning patients do not need to travel overseas to access investigational regenerative options. That said, availability does not equal endorsement. The science remains early, and honest conversations about what is known and unknown are essential.
What to Expect: A Month-by-Month Timeline
Individual timelines vary widely, but a general outline for those who proceed with stem cell therapy might look like this:
Month 1: Initial evaluation, imaging review, lab work, informed consent discussion. If you move forward, cells are typically harvested (if autologous) or prepared (if allogeneic) and delivered via intra-articular injection. Immediate activity restrictions may apply—your physician will provide specific guidance.
Months 2–3: Early inflammatory response may cause temporary discomfort or swelling. Pain levels often remain similar to baseline or fluctuate. Physical therapy may begin to support joint mobility and muscle strength.
Months 4–6: Some patients report gradual pain reduction and improved function; others notice little change. Follow-up imaging is sometimes ordered to assess cartilage or other structural markers, though correlation between imaging and symptoms is imperfect.
Months 7–12: If benefit occurs, it tends to plateau by this point. Long-term data beyond one to two years remain limited in most published trials. Some people maintain improvement; others regress or require additional interventions.
This timeline is illustrative, not prescriptive. Responses vary, and individual timelines differ. Honest communication with your physician throughout the process helps manage expectations and adjust the plan as needed.
How long does it take to see results from knee stem cell therapy?
Most published studies report that participants who experience improvement notice gradual changes over three to six months, with effects plateauing by one year. Some people report earlier benefit; others see little change at any time point. The variability reflects differences in individual biology, baseline severity, and the investigational nature of the therapy itself.
Do I need to travel overseas for Muse cell therapy?
No. Physician-supervised Muse cell therapy is available in the United States. While some regenerative therapies have historically required international travel, investigational options are now accessible domestically under appropriate medical oversight. That accessibility does not change the investigational status or the need for realistic expectations.
Will insurance cover stem cell therapy for knee pain?
Most insurance plans do not cover investigational stem cell therapies for knee osteoarthritis or other musculoskeletal conditions because the FDA has not approved these interventions. Patients typically pay out of pocket. Costs vary by provider, cell source, and whether additional services (imaging, lab work, follow-up visits) are included. Ask for a detailed cost breakdown during the initial consultation.
What happens if stem cell therapy doesn't work for my knee?
If you do not experience meaningful improvement after several months, your physician will reassess. Conventional options—continued physical therapy, weight management, anti-inflammatory medications, or surgical consultation—remain available. Stem cell therapy is not a last resort that closes other doors; it is one investigational option among several, and candidacy for surgery or other interventions does not disappear if regenerative approaches do not deliver the hoped-for result.
At Springs Rejuvenation, stem cell and exosome therapies are used together as part of a personalized regenerative protocol.
Medical Disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Springs Rejuvenation processes exosomes in an FDA approved lab. Individual results may vary. This content is reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director of Springs Rejuvenation, and is provided for educational purposes only. Always consult a qualified physician.